Tests dapagliflozin in adults with atrial fibrillation after cardioversion
Compares dapagliflozin with usual care in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Key facts
- Where
- Danderyd, Huddinge, Linkoping, Orebro, Stockholm, Umea, and Uppsala, SwedenSee the 7 sites
- Phase
- Phase 3
Where in Sweden
- Danderyds Sjukhus ABDanderyd, SwedenTaking people
- Karolinska University HospitalHuddinge, SwedenTaking people
- Region OestergoetlandLinkoping, SwedenTaking people
- Region Oerebro LaenOrebro, SwedenTaking people
- Soedersjukhuset ABStockholm, SwedenTaking people
- Region VaesterbottenUmea, SwedenTaking people
- Uppsala University HospitalUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Stockholm
- Trial code
- NCT07187570EU 2024-513719-28-00
- Record updated
- 23 September 2025
- Original description
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:Read full original descriptionShow less
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:
• Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation?
Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.
Persons with atrial fibrillation who are planned for an electric cardioversion will:
* Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days
Inclusion: Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date; Age ≥ 55 years; Provided written informed consent.
Exclusion: Current treatment with an SGLT2 inhibitor; Prior/current diagnosis of heart failure; Contraindications to SGLT2 inhibitors; Type 1 diabetes mellitus; Any condition or circumstance in which the patient should not participate in the study according to the study investigator; Estimated glomerular filtration rate (eGFR) < 25 mL/min/1.73m2; Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).